{"ticker": {"uuid": "093a547b-93a5-43da-a687-bc6db82bd703", "symbol": "4151", "name": "Kyowa Kirin Co., Ltd.", "exchange": "JPX", "country": "JP", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Kyowa Kirin Co Ltd (4151) Stock, Price, News, Quotes, Forecast and Insights | MSN Money", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPS0M5cUUzelU5SjVOTHdIMHp6cmpmTUt4dk1paGpqenRRUnJRdkJxcjNnWWlBSnp2WVMtdXNCSXJTN3V6OFdHWEVWT0RPZGd6RHdORGJiMmhCX2QydVRtaldJNjlXMkE1ckZocHhvai1DNW1UUGtqQXZYTEswa0lwZ1g5THdoOTJDTVV0cA?oc=5", "source_name": "MSN", "published_at": "2026-07-14T11:38:37+00:00", "published_display": "14 Jul 2026 11:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyowa Kirin Co Ltd (4151)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPVmVpUklKd3JhVWtRWEZjTWpEeVFWTzRuS2tUYUZHcHBUNnFRcUJPU0M4Q0FFckc1Y3pkN0FTT0VvUE42UnZDangtcEtNckF2bFQzT3JqTERSMVpsaVNfRG05RGRnUzc1R25ERGRqM01QTXhnOVRFajBDN0JfWEk0QmhuTVQ?oc=5", "source_name": "MSN", "published_at": "2026-07-14T06:00:41+00:00", "published_display": "14 Jul 2026 06:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyowa Kirin outlines growth path as specialty pharma focus deepens", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOMm1QQ0V5aGNjdkR1OXBJNTh6MDNlQ3RyOU1TZk9RamxCZVFBOEVnd1pHWmNjVlktSjdUU0d6cU9Td3dWeF9JV1g1MUpjTXA3UHptX0Ixenh1ZEgtX0N0c0pEcWE4NFhvRElvN0s1LVpoc3lLYkNaRi1DUUtwdmxNRXZ3cG83eDM0ZVBVTlZqQ2hIcHdvakREOHpzZW1KdmowQUJSSTMwSHEzMVN0X3BwN0JYNGFQY1JfUms0YXZ5aktVSDg?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyowa Kirin discontinues rocatinlimab trials due to safety issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZlBObm92VTB2NVRKRVp4OEFlaGpSelNWWXg5TGs3c29XMktoN0xOQ3RUZHNaWVJCMmdJVTdieUlSb05TbmZBTkpqdzFyMkp5MWRrdE5QLUhsNzFjRml3TXRXTVFNNDkwRWhpLS1oTXIwNVdGcW96LVlLMFV6Z2FOSWJ4QTFtdzdVSlRIVWtLa19HNjFfMWY4R2lBdVV1bUVWcU5mSEdSNzQydw?oc=5", "source_name": "BioWorld News", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Kura-Kyowa's blood cancer therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPY3ZZQVFvT0Iya2xMU3lqWHM2bzVJYVBUNnhtX2M1Vnc1bTdsdnlzSTYwZlB5MDJvaU5tZWNRbFpSbzlXNmNMUHlqbnpmaGl5OXRKOHdKWGF4aGVabjVGVno0VlRDMjN2SGVmSS1pRndRRVNXLU9zNGstSUFOY2ZPWjVhWU5ZQTkzemp6S1VyYXBJaDJzcHdnRGRNZnZCR0FhTTVIcFFMSGZnczlHVm10SGljS0lKMmJsc2xxQkN6ekg?oc=5", "source_name": "Reuters", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugJBVV95cUxOUXB6UnZBT3NxalBqQVZPV2poUjRrazJvTEt5UW5QUzVqVUNYMUFXdjViMU1CWlpYQVdQOUNkbjh0MllHc1ZtaS1aTmUyRXZoNWhzU0V3bkVDeGhydTJhMDFMaUVMZnljTnkwTnFZUmVzRnRkV1RKOTVBbXRSdEwyWUpQWmtqVUstS3Vza1RyWklJNTFhb0VEc0gtTDhyR0NwWkhsOFdrQUpTMUZLTG5pUjBVZGlvN0N6VXlNVUtQSzBXVXJPdy1FdGlWNjRKVDNvSmFIMWtULWtsbk8tSWtUTFROdlh4UGg4bnpIT2ZMUHFmOEdSbGRRNVJ2R2paZC1qMUFzLVByTmg1WmFURHZ5d2J6d29DMnF6bkprVzVSclVpc1AwTjFDbHNZS0lGRjNwcFVqTkZiekpFUQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-08T07:00:00+00:00", "published_display": "08 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS", "summary": "", "url": "https://news.google.com/rss/articles/CBMingJBVV95cUxObHRFdHZSN21SQmZURXctcWo0aVpUOWJsUTZRd3I5blduZktLVzNnNk8zU0lsU3RraUMxLXVoaHRSNnNRX05HRjRKSFY3QTRIWU1kSzIyTzZoVnVGRXg2VFJlVWVKdG1QSEVQNUUyVG16Um9qSWotWFFhb0htQnRyZ3RGOVBuU0d5ODJPalFHTmZGcnRPNmpNaUhFNjR4THdQV192R3NuYWpVdUF4S2pKaEZKS3FaanBVaVM2bGduUUhjOXN0X2ZxYVNINlBYVzVVMDAzcFdHOHh3WTJTMURVaG5qMXBpVW5uRXFoMHNLUllXdlFXMnB4cHNuTG9Mdm9vd2paVlBtSm95X3RvT2k0YTJwc1pXWjNPSFJsbmVR?oc=5", "source_name": "PR Newswire", "published_at": "2025-03-08T08:00:00+00:00", "published_display": "08 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyowa Kirin Co., Ltd. Earnings and Revenue \u2013 TSE:4151", "summary": "", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE80S0tQd3ZNNE9FckJ4a3UyR3dpYnh1Mmx2UUdxUmdzcndrWDNSanZVTGVHX3ZhXzNQMWhSc2t0R284a0JQeFdXSXJla2tMd2FMSlpWVkdOQS1BQmYxRzlEVmc3ZjhfMGtZc1VYcmZyV2Q5RW8?oc=5", "source_name": "TradingView", "published_at": "2023-07-12T11:39:34+00:00", "published_display": "12 Jul 2023 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lupin Offloads Kyowa Pharma For $525m But Not Exiting Japan", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPUlNJM3VwbFJoa1BVZnVvVlNHeWsxX21WbWowZGRCVnh2MHR3bXFjSVRFX2YyUkhodmljU1VyY0ZMTGtYZzYwSU91RVVFNkpRVVk0SjhPVWktQjN4MFJUdTlKUXdyN2RwcWd1T2JmWDUzZ255NmRNOFhSWjlPRjE5MjZsSkpGdGpSRVVqOEJnMEx6UjExTDJjdV9zdGc2Sk1a?oc=5", "source_name": "insights.citeline.com", "published_at": "2019-11-11T08:00:00+00:00", "published_display": "11 Nov 2019 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Kyowa Kirin Co Ltd (4151) Stock, Price, News, Quotes, Forecast and Insights | MSN Money", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPS0M5cUUzelU5SjVOTHdIMHp6cmpmTUt4dk1paGpqenRRUnJRdkJxcjNnWWlBSnp2WVMtdXNCSXJTN3V6OFdHWEVWT0RPZGd6RHdORGJiMmhCX2QydVRtaldJNjlXMkE1ckZocHhvai1DNW1UUGtqQXZYTEswa0lwZ1g5THdoOTJDTVV0cA?oc=5", "source_name": "MSN", "published_at": "2026-07-14T11:38:37+00:00", "published_display": "14 Jul 2026 11:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyowa Kirin Co Ltd (4151)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPVmVpUklKd3JhVWtRWEZjTWpEeVFWTzRuS2tUYUZHcHBUNnFRcUJPU0M4Q0FFckc1Y3pkN0FTT0VvUE42UnZDangtcEtNckF2bFQzT3JqTERSMVpsaVNfRG05RGRnUzc1R25ERGRqM01QTXhnOVRFajBDN0JfWEk0QmhuTVQ?oc=5", "source_name": "MSN", "published_at": "2026-07-14T06:00:41+00:00", "published_display": "14 Jul 2026 06:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyowa Kirin outlines growth path as specialty pharma focus deepens", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOMm1QQ0V5aGNjdkR1OXBJNTh6MDNlQ3RyOU1TZk9RamxCZVFBOEVnd1pHWmNjVlktSjdUU0d6cU9Td3dWeF9JV1g1MUpjTXA3UHptX0Ixenh1ZEgtX0N0c0pEcWE4NFhvRElvN0s1LVpoc3lLYkNaRi1DUUtwdmxNRXZ3cG83eDM0ZVBVTlZqQ2hIcHdvakREOHpzZW1KdmowQUJSSTMwSHEzMVN0X3BwN0JYNGFQY1JfUms0YXZ5aktVSDg?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyowa Kirin discontinues rocatinlimab trials due to safety issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZlBObm92VTB2NVRKRVp4OEFlaGpSelNWWXg5TGs3c29XMktoN0xOQ3RUZHNaWVJCMmdJVTdieUlSb05TbmZBTkpqdzFyMkp5MWRrdE5QLUhsNzFjRml3TXRXTVFNNDkwRWhpLS1oTXIwNVdGcW96LVlLMFV6Z2FOSWJ4QTFtdzdVSlRIVWtLa19HNjFfMWY4R2lBdVV1bUVWcU5mSEdSNzQydw?oc=5", "source_name": "BioWorld News", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Kura-Kyowa's blood cancer therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPY3ZZQVFvT0Iya2xMU3lqWHM2bzVJYVBUNnhtX2M1Vnc1bTdsdnlzSTYwZlB5MDJvaU5tZWNRbFpSbzlXNmNMUHlqbnpmaGl5OXRKOHdKWGF4aGVabjVGVno0VlRDMjN2SGVmSS1pRndRRVNXLU9zNGstSUFOY2ZPWjVhWU5ZQTkzemp6S1VyYXBJaDJzcHdnRGRNZnZCR0FhTTVIcFFMSGZnczlHVm10SGljS0lKMmJsc2xxQkN6ekg?oc=5", "source_name": "Reuters", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugJBVV95cUxOUXB6UnZBT3NxalBqQVZPV2poUjRrazJvTEt5UW5QUzVqVUNYMUFXdjViMU1CWlpYQVdQOUNkbjh0MllHc1ZtaS1aTmUyRXZoNWhzU0V3bkVDeGhydTJhMDFMaUVMZnljTnkwTnFZUmVzRnRkV1RKOTVBbXRSdEwyWUpQWmtqVUstS3Vza1RyWklJNTFhb0VEc0gtTDhyR0NwWkhsOFdrQUpTMUZLTG5pUjBVZGlvN0N6VXlNVUtQSzBXVXJPdy1FdGlWNjRKVDNvSmFIMWtULWtsbk8tSWtUTFROdlh4UGg4bnpIT2ZMUHFmOEdSbGRRNVJ2R2paZC1qMUFzLVByTmg1WmFURHZ5d2J6d29DMnF6bkprVzVSclVpc1AwTjFDbHNZS0lGRjNwcFVqTkZiekpFUQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-08T07:00:00+00:00", "published_display": "08 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS", "summary": "", "url": "https://news.google.com/rss/articles/CBMingJBVV95cUxObHRFdHZSN21SQmZURXctcWo0aVpUOWJsUTZRd3I5blduZktLVzNnNk8zU0lsU3RraUMxLXVoaHRSNnNRX05HRjRKSFY3QTRIWU1kSzIyTzZoVnVGRXg2VFJlVWVKdG1QSEVQNUUyVG16Um9qSWotWFFhb0htQnRyZ3RGOVBuU0d5ODJPalFHTmZGcnRPNmpNaUhFNjR4THdQV192R3NuYWpVdUF4S2pKaEZKS3FaanBVaVM2bGduUUhjOXN0X2ZxYVNINlBYVzVVMDAzcFdHOHh3WTJTMURVaG5qMXBpVW5uRXFoMHNLUllXdlFXMnB4cHNuTG9Mdm9vd2paVlBtSm95X3RvT2k0YTJwc1pXWjNPSFJsbmVR?oc=5", "source_name": "PR Newswire", "published_at": "2025-03-08T08:00:00+00:00", "published_display": "08 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyowa Kirin Co., Ltd. Earnings and Revenue \u2013 TSE:4151", "summary": "", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE80S0tQd3ZNNE9FckJ4a3UyR3dpYnh1Mmx2UUdxUmdzcndrWDNSanZVTGVHX3ZhXzNQMWhSc2t0R284a0JQeFdXSXJla2tMd2FMSlpWVkdOQS1BQmYxRzlEVmc3ZjhfMGtZc1VYcmZyV2Q5RW8?oc=5", "source_name": "TradingView", "published_at": "2023-07-12T11:39:34+00:00", "published_display": "12 Jul 2023 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lupin Offloads Kyowa Pharma For $525m But Not Exiting Japan", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPUlNJM3VwbFJoa1BVZnVvVlNHeWsxX21WbWowZGRCVnh2MHR3bXFjSVRFX2YyUkhodmljU1VyY0ZMTGtYZzYwSU91RVVFNkpRVVk0SjhPVWktQjN4MFJUdTlKUXdyN2RwcWd1T2JmWDUzZ255NmRNOFhSWjlPRjE5MjZsSkpGdGpSRVVqOEJnMEx6UjExTDJjdV9zdGc2Sk1a?oc=5", "source_name": "insights.citeline.com", "published_at": "2019-11-11T08:00:00+00:00", "published_display": "11 Nov 2019 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 72, "total_relevant": 9, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 8, "score": 51, "total": 9, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 3.1, "count": 5}, {"event": "earnings", "label": "Earnings", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 2641.0, "latest_week": "2026-07-10", "one_week_move": -0.8, "four_week_move": 11.6, "twelve_week_move": 7.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.655716, "market_dynamics_buy_signal": false, "relative_strength": -18.977894, "fair_value_gap": 7.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.0464, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.8% over one week, +11.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 48, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "MSN", "count": 2}, {"label": "PR Newswire", "count": 2}, {"label": "ad-hoc-news.de", "count": 1}, {"label": "BioWorld News", "count": 1}, {"label": "Reuters", "count": 1}, {"label": "TradingView", "count": 1}, {"label": "insights.citeline.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 9}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 5}, {"label": "Earnings", "count": 3}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "9", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.8% over one week, +11.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Kyowa Kirin Co Ltd (4151) Stock, Price, News, Quotes, Forecast and Insights | MSN Money"}], "updated_at": "2026-07-17T00:41:04.213943+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}